These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21999825)

  • 1. Can a simple proteomics urine test assist in the early diagnosis of early-stage cancer?
    Husi H; Fearon KC; Ross JA
    Expert Rev Proteomics; 2011 Oct; 8(5):555-7. PubMed ID: 21999825
    [No Abstract]   [Full Text] [Related]  

  • 2. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers.
    Slupsky CM; Steed H; Wells TH; Dabbs K; Schepansky A; Capstick V; Faught W; Sawyer MB
    Clin Cancer Res; 2010 Dec; 16(23):5835-41. PubMed ID: 20956617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of urinary nucleosides. V. Identification of urinary pyrimidine nucleosides by liquid chromatography/electrospray mass spectrometry.
    Bond A; Dudley E; Lemière F; Tuytten R; El-Sharkawi S; Brenton AG; Esmans EL; Newton RP
    Rapid Commun Mass Spectrom; 2006; 20(2):137-50. PubMed ID: 16331740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different sample preparation and detection methods for normal and lung cancer urinary proteome analysis.
    Sinchaikul S; Tantipaiboonwong P; Sriyam S; Tzao C; Phutrakul S; Chen ST
    Methods Mol Biol; 2010; 641():65-88. PubMed ID: 20407942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics as a tool for detection of nuclear matrix proteins and new biomarkers for screening of early tumors stage.
    Oehr P
    Anticancer Res; 2003; 23(2A):805-12. PubMed ID: 12820304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary modified nucleosides as tumor markers.
    Dudley E; Lemiere F; Van Dongen W; Esmans E; El-Sharkawi AM; Games DE; Brenton AG; Newton RP
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):987-9. PubMed ID: 14565327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.
    Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD
    Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of urinary proteomics/peptidomics.
    Albalat A; Mischak H; Mullen W
    Expert Rev Proteomics; 2011 Oct; 8(5):615-29. PubMed ID: 21999832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
    Bharti A; Ma PC; Salgia R
    Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes.
    Fliser D; Wittke S; Mischak H
    Electrophoresis; 2005 Jul; 26(14):2708-16. PubMed ID: 15966014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometry: uncovering the cancer proteome for diagnostics.
    van der Merwe DE; Oikonomopoulou K; Marshall J; Diamandis EP
    Adv Cancer Res; 2007; 96():23-50. PubMed ID: 17161675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteins' promise--progress and challenges in ovarian cancer proteomics.
    Koehn H; Oehler MK
    Menopause Int; 2007 Dec; 13(4):148-53. PubMed ID: 18088525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome.
    Cho WC
    Expert Rev Proteomics; 2011 Feb; 8(1):1-4. PubMed ID: 21329422
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical proteomics and mass spectrometry profiling for cancer detection.
    Solassol J; Jacot W; Lhermitte L; Boulle N; Maudelonde T; Mangé A
    Expert Rev Proteomics; 2006 Jun; 3(3):311-20. PubMed ID: 16771703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of urinary proepithelin as a potential biomarker for bladder cancer detection and prognosis in Egyptian patients.
    Selmy MA; Ibrahim GH; El Serafi TI; Ghobeish AA
    Cancer Biomark; 2010; 7(3):163-70. PubMed ID: 21263192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urine-based oncological diagnostic for bladder carcinoma: what is new?].
    Rübben H
    Urologe A; 2009 Jun; 48(6):597. PubMed ID: 19557463
    [No Abstract]   [Full Text] [Related]  

  • 17. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.
    Cao DL; Ye DW; Zhu Y; Zhang HL; Wang YX; Yao XD
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):166-72. PubMed ID: 21321584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer.
    Hanke M; Hoefig K; Merz H; Feller AC; Kausch I; Jocham D; Warnecke JM; Sczakiel G
    Urol Oncol; 2010; 28(6):655-61. PubMed ID: 19375957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Telomerase activity: a molecular marker for early diagnosis of bladder tumor].
    Calistri D; Sanchini A; Amadori D; Silvestrini R
    Recenti Prog Med; 2007 Feb; 98(2):74-8. PubMed ID: 17439065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.